Veracyte Inc Dossier - Source-backed chat

Veracyte Inc

VCYTNASDAQ

SectorHealth Care

IndustryDiagnostics & Research

Beta (adjusted)1.61

Intrinsic Value $26.78median of 5 methods · middle span $19-$27based on filings through 30 Jun 2026

Market Price $46.04Price as of 30 Sep 2026

OvervaluedIntrinsic value is 42% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $3.7B

Enterprise Value $3.4B

Shares Outstanding 82.4M diluted

Moat Rating None

Next Earnings Date3 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Veracyte is successfully transitioning from a specialized diagnostic laboratory into a highly profitable, multi-cancer genomic decision platform. The company's core franchises, Decipher (prostate cancer) and Afirma (thyroid nodules), continue to deliver robust double-digit volume growth and command high pricing power, driving non-GAAP gross margins to 76%. With the upcoming commercial launches of TrueMRD and Prosigna LDT, Veracyte is poised to expand its total addressable market (TAM) from $12 billion to $50 billion. Strong operating leverage, a debt-free balance sheet, and robust cash generation support sustainable GAAP profitability, making it a highly attractive asset in the precision medicine space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$44.00

Mean target$57.82

High · most bullish analyst$70.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$44.00

Tightening reimbursement landscapes or unexpected coverage denials from Medicare/private payers for Afirma or Decipher tests. TrueMRD faces intense competitive pressure from established MRD players like Natera (Signatera), resulting in slower-than-expected market penetration and higher commercialization costs that compress operating margins.

Base CaseCentral scenario

$57.82

Matches the consensus mean

Core Afirma and Decipher franchises maintain steady 12% to 14% volume growth, supported by strong clinical evidence and established physician workflows. TrueMRD achieves moderate initial commercial ramp in muscle-invasive bladder cancer. Total revenue grows to the raised full-year 2026 guidance of $582 million to $592 million, with adjusted EBITDA margins stabilizing around 25% to 30%.

Bull CaseUpside scenario

$70.00

Perfect execution of the TrueMRD platform launch following the C2i Genomics acquisition, capturing a significant share of the $20 billion cancer recurrence monitoring market. Rapid commercial adoption of Prosigna LDT in breast cancer and continued 20%+ volume growth in Decipher Prostate drive operating leverage, pushing GAAP net margins to 20% and accelerating annual revenue growth beyond 20%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

High-margin business model with non-GAAP testing gross margins reaching 76%, demonstrating software-like operating leverage as testing volumes scale.
Dominant market leadership in thyroid (Afirma) and prostate (Decipher) genomic testing, backed by deep clinical evidence and inclusion in major medical guidelines (NCCN).
Robust financial position with $439.1 million in cash, cash equivalents, and short-term investments, and virtually zero debt, enabling strategic flexibility and self-funded pipeline expansion.

Key Investment Risks

Reimbursement risk, as financial performance is highly dependent on coverage decisions and average selling prices (ASPs) set by Medicare and private payers.
Intense competition in the minimal residual disease (MRD) space from well-capitalized competitors such as Natera, Guardant Health, and Exact Sciences.
Execution risk associated with the commercial integration and scaling of newly acquired technologies (e.g., C2i Genomics platform).

Thesis Invalidation Triggers

A significant downward revision in Medicare reimbursement rates or non-coverage decisions for Decipher or Afirma tests.
Failure of TrueMRD to secure Medicare coverage or clinical guideline inclusion within 18 months of launch.
A material deceleration in core testing volume growth below 10% year-over-year.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.